Illumina Inc (ILMN) reports robust Q1 performance with increased revenue and EPS, while raising 2026 guidance amid strong clinical market demand.

Q1 2026 Management View Jacob Thaysen opened by saying, "We are off to a great start in 2026 with Q1 revenue, margin and EPS all coming in above our guidance range," adding that performance reflected ...

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up ...

For the quarter ended March 2026, Illumina (ILMN) reported revenue of $1.09 billion, up 4.8% over the same period last year. EPS came in at $1.15, compared to $0.97 in the year-ago quarter. The ...